€32.80
0.46% today
Xetra, Oct 16, 09:01 am CET
ISIN
DE000A2GS5D8
Symbol
DMP
Index

Dermapharm Stock price

€32.95
+0.30 0.92% 1M
-4.70 12.48% 6M
-5.95 15.30% YTD
+1.00 3.13% 1Y
-7.03 17.58% 3Y
-9.90 23.09% 5Y
+6.95 26.73% 10Y
+6.95 26.73% 20Y
Xetra, Closing price Wed, Oct 15 2025
+0.25 0.76%
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Industry

Key metrics

Basic
Market capitalization
€1.8b
Enterprise Value
€2.6b
Net debt
€843.7m
Cash
€165.9m
Shares outstanding
53.8m
Valuation (TTM | estimate)
P/E
16.6 | 14.3
P/S
1.5 | 1.5
EV/Sales
2.2 | 2.2
EV/FCF
14.8
P/B
2.9
Dividends
DPS
€0.90
Yield 1Y | 5Y
2.7% | 2.4%
Growth 1Y | 5Y
2.3% | 2.4%
Payout 1Y | 3Y
42.7% | 49.1%
Increased
1 Year
Financials (TTM | estimate)
Revenue
€1.2b | €1.2b
EBITDA
€305.5m | €330.1m
EBIT
€218.3m | €236.7m
Net Income
€107.2m | €124.4m
Free Cash Flow
€175.4m
Growth (TTM | estimate)
Revenue
4.0% | 1.0%
EBITDA
5.4% | 7.9%
EBIT
14.2% | 3.9%
Net Income
29.1% | 9.4%
Free Cash Flow
20.5%
Margin (TTM | estimate)
Gross
65.7%
EBITDA
26.0% | 27.7%
EBIT
18.6%
Net
9.1% | 10.4%
Free Cash Flow
14.9%
Financial Health
Equity Ratio
29.1%
Return on Equity
18.8%
ROCE
12.3%
ROIC
8.3%
Debt/Equity
1.7
More
EPS
€2.0
FCF per Share
€3.3
Short interest
-
Employees
4k
Rev per Employee
€330.0k
Show more

Is Dermapharm a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Dermapharm Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Dermapharm forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Dermapharm forecast:

Buy
73%
Hold
27%

Financial data from Dermapharm

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,177 1,177
4% 4%
100%
- Direct Costs 404 404
0% 0%
34%
773 773
6% 6%
66%
- Selling and Administrative Expenses 287 287
4% 4%
24%
- Research and Development Expense - -
-
-
306 306
5% 5%
26%
- Depreciation and Amortization 87 87
12% 12%
7%
EBIT (Operating Income) EBIT 218 218
14% 14%
19%
Net Profit 107 107
29% 29%
9%

In millions EUR.

Don't miss a Thing! We will send you all news about Dermapharm directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dermapharm Stock News

AD HOC NEWS
about 2 months ago
Das Analysehaus Jefferies hat das Kursziel für die Aktien von Dermapharm DE000A2GS5D8 von 49 auf 34 Euro gesenkt und die Papiere von "Buy" auf "Hold" abgestuft.
More Dermapharm News

Company Profile

Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.

Head office Germany
CEO Hans-Georg Feldmeier
Employees 3,610
Founded 1991
Website ir.dermapharm.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today